[ADAP] Adaptimmune Therapeutics plc


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.05 Change: 0.06 (1.5%)
Ext. hours: Change: 0 (0%)

chart ADAP

Refresh chart

Strongest Trends Summary For ADAP

ADAP is in the medium-term down -59% below S&P in 1 year and down -80% below S&P in 1 year. In the long-term down -95% below S&P in 3 years and down -97% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities60.55 M Cash From Investing Activities-17.16 M Cash From Operating Activities-9.73 M Gross Profit
Net Profit-3.12 M Operating Profit-5.16 M Total Assets88.48 M Total Current Assets86.65 M
Total Current Liabilities29.46 M Total Debt Total Liabilities29.46 M Total Revenue2.44 M
Technical Data
High 52 week14.16 Low 52 week1.01 Last close1.02 Last change0%
RSI12.64 Average true range0.14 Beta1.29 Volume75.45 K
Simple moving average 20 days-25.6% Simple moving average 50 days-35.19% Simple moving average 200 days-71.22%
Performance Data
Performance Week0.99% Performance Month-43.33% Performance Quart-69.55% Performance Half-75.94%
Performance Year-91.78% Performance Year-to-date-82.26% Volatility daily4.43% Volatility weekly9.91%
Volatility monthly20.31% Volatility yearly70.35% Relative Volume821.28% Average Volume349.73 K
New High New Low


2020-05-19 07:02:00 | Where Will Adaptimmune Be in 5 Years?

2020-05-15 08:27:07 | Edited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMT

2020-05-14 12:00:27 | Adaptimmune Therapeutics PLC ADAP Q1 2020 Earnings Call Transcript

2020-05-14 08:55:46 | Recap: Adaptimmune Therapeutics Q1 Earnings

2020-05-14 07:30:10 | Adaptimmune Reports Q1 Financial Results

2020-05-12 08:00:10 | SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting

2020-05-12 06:07:26 | What Kind Of Share Price Volatility Should You Expect For Adaptimmune Therapeutics plc NASDAQ:ADAP?

2020-04-29 08:00:10 | Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020

2020-04-28 12:00:04 | What Makes Adaptimmune Therapeutics PLC ADAP a New Strong Buy Stock

2020-04-28 08:00:10 | Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products

2020-03-19 13:10:23 | Edited Transcript of ADAP earnings conference call or presentation 27-Feb-20 1:00pm GMT

2020-03-11 11:35:02 | Passage Bio's IPO tops out at $248.4M after options exercised

2020-03-11 11:35:02 | Passage Bio's IPO tops out at $248.4M after options exercised

2020-02-29 08:31:10 | Earnings Update: Adaptimmune Therapeutics plc Just Reported And Analysts Are Boosting Their Estimates

2020-02-27 07:30:10 | Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update

2020-02-27 06:00:00 | Adaptimmune Therapeutics Plc to Host Earnings Call

2020-02-24 15:15:06 | After leadership overhaul, Adaptimmune targets first cell therapy product launch

2020-02-20 16:00:10 | Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020

2020-02-18 08:00:10 | Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer

2020-02-07 16:05:10 | Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares

2020-02-05 11:30:04 | Has Adaptimmune Therapeutics ADAP Outpaced Other Medical Stocks This Year?

2020-02-03 09:13:02 | Adaptimmune Therapeutics plc ADAP Shares March Higher, Can It Continue?

2020-01-24 16:30:10 | Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares

2020-01-22 13:18:05 | Philadelphia cell therapy company prices $84M public stock offering

2020-01-22 08:48:42 | Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

2020-01-22 08:25:41 | The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

2020-01-22 06:48:11 | Top Ranked Momentum Stocks to Buy for January 22nd

2020-01-21 16:08:54 | Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

2020-01-17 12:00:05 | What Makes Adaptimmune Therapeutics PLC ADAP a New Buy Stock

2020-01-15 08:22:46 | The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

2020-01-14 12:29:44 | After a Massive Gain, Is There Still Room for Adaptimmune ADAP Stock to Soar?

2020-01-14 07:55:40 | The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

2020-01-14 02:08:01 | Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

2020-01-13 08:30:10 | Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership

2020-01-13 02:00:10 | Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

2019-12-30 05:25:50 | Adaptimmune Therapeutics NASDAQ:ADAP Will Have To Spend Its Cash Wisely

2019-12-16 05:45:38 | Is Adaptimmune Therapeutics plc ADAP Going To Burn These Hedge Funds ?

2019-12-03 14:20:52 | Adaptimmune gets FDA designation to accelerate development of cancer therapy

2019-12-03 08:30:10 | Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP?A2M4 for the Treatment of Synovial Sarcoma

2019-11-16 02:00:00 | Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma

2019-11-14 15:19:50 | Edited Transcript of ADAP earnings conference call or presentation 6-Nov-19 1:00pm GMT

2019-11-06 07:30:00 | Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update

2019-11-01 08:00:05 | Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019

2019-10-31 13:52:52 | Is Adaptimmune Therapeutics plc ADAP Is Burning These Hedge Funds

2019-10-31 06:09:41 | Do Directors Own Adaptimmune Therapeutics plc NASDAQ:ADAP Shares?

2019-10-09 08:00:00 | Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies

2019-10-01 08:00:00 | Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer

2019-09-30 08:45:00 | Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO

2019-09-16 06:41:29 | Does The Adaptimmune Therapeutics plc NASDAQ:ADAP Share Price Fall With The Market?

2019-09-10 09:01:01 | Adaptimmune ADAP Gets Orphan Drug Status for T-cell Therapy